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S U M M A R Y
Objectives: To analyze the prevalence of hepatitis B virus (HBV) co-infection and its inﬂuence on
mortality and treatment outcome within a large AIDS cohort in Chile.
Methods: Clinical and epidemiological data from the Chilean AIDS Cohort were retrospectively analyzed.
Adult patients tested for hepatitis B surface antigen (HBsAg) during the time period of October 2001 to
October 2007 were included.
Results: Of 5115 cohort patients, 1907 met the inclusion criteria. The prevalence of HBV co-infection was
8.4%. Overall mortality rates were 2.15 and 1.77 per 100 person-years for HBsAg-positive and HBsAg-
negative HIV patients, respectively, with a mortality rate ratio of 1.22 (95% conﬁdence interval 0.58–
2.54). Kaplan–Meier survival and Cox regression analysis did not show signiﬁcant differences between
the groups. Virological and immunological responses to antiretroviral therapy (ART) were not inﬂuenced
by HBsAg status, but in co-infected patients, initial ART was more frequently changed.
Conclusions: The prevalence of hepatitis B co-infection was 8.4%, indicating a markedly elevated
hepatitis B risk compared to the general population in Chile. Neither treatment outcome nor overall
mortality was inﬂuenced by hepatitis B co-infection. Still, patients with hepatitis B co-infection had less
stable ART regimens, which might be related to a higher risk of hepatotoxic drug effects.
 2013 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
Contents lists available at SciVerse ScienceDirect
International Journal of Infectious Diseases
jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Antiretroviral therapy (ART) has increased life expectancy and
quality of life of HIV-infected individuals by suppressing viral
replication. In this setting, co-morbidities such as chronic viral
infections are gaining importance in the management of HIV.
Hepatitis B is a frequent co-infection with a similar mode of
transmission and has been recognized as a challenge worldwide.1
About 10% of all HIV-positive patients are co-infected with the
hepatitis B virus (HBV).2 Factors inﬂuencing the prevalence of this
co-infection include the predominant mode of HIV transmission
and the prevalence of HBV in the population of the country, which
ranges between 0.1% and 20% worldwide.3 Chile belongs to the low
endemic countries. Recent data from the Chilean Ministry of
Health show a prevalence of only 0.15% chronic HBV in the general
population.4 In Chile as much as 84% of HBVs belong to genotype
F,5 which has been associated with higher mortality and incidence* Corresponding author. Tel.: +56 2 2210 1006; fax: +56 2 2210 1153.
E-mail addresses: thomas.weitzel@gmail.com, tweitzel@alemana.cl (T. Weitzel).
1201-9712/$36.00 – see front matter  2013 Published by Elsevier Ltd on behalf of In
http://dx.doi.org/10.1016/j.ijid.2013.05.009of hepatocellular carcinoma.6 There are very few epidemiological
data on HBV/HIV co-infection in Chile. A publication by Pe´rez et al.
reported a prevalence of 6.1% of hepatitis B surface antigen
(HBsAg) carriers among 311 HIV patients in a private HIV center in
Santiago.7
There are still many uncertainties about the clinical relevance of
viral co-infection with HBV and HIV and the inﬂuence of ART. In the
pre-ART era, some studies described a faster progression to AIDS8
and reduced survival for co-infected patients.9 Others did not ﬁnd
any impact on the progression of HIV infection.10,11 Later studies
under ART showed conﬂicting results regarding mortality and AIDS
progression. The majority of studies showed a higher liver-related
mortality associated with HBV co-infection for HIV patients under
ART,12–14 while virological or immunological response to ART did
not seem to be inﬂuenced.15–20
Regarding discordant responses to ART, i.e., an adequate
virological without immunological response, or vice versa, the
situation in HBV co-infected patients is unclear. This phenomenon
is associated with a worse clinical outcome regarding mortality
and AIDS-deﬁning events.21–24 Well-known risk factors for
discordant responses include age, low CD4+ cell count nadir, highternational Society for Infectious Diseases.
Figure 1. Flow chart: patient numbers for subgroup analysis and patient numbers
for drop out (HBsAg, hepatitis B surface antigen; VL, viral load).
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ART combinations, and adherence problems.24–27 A small series
from Spain did not ﬁnd an association with hepatitis C co-
infection,28 while HBV co-infection as a risk factor for discordant
treatment outcome has not been investigated so far. Remarkably,
most of the studies mentioned above were performed in
industrialized countries, while data from low- or middle-income
countries, with their limited diagnostic and treatment options for
both hepatitis B and HIV, are scarce.
In this study, data from the Chilean AIDS Cohort, a national joint
project that follows clinical information and treatment data of HIV
patients receiving ART within the Chilean public health system,29
were used to retrospectively analyze the prevalence of HBV co-
infection in Chile, as well as the possible inﬂuence of HBV co-
infection on mortality and the virological and immunological
treatment response, including discordant response, after 12
months of ART.
2. Methods
The Chilean AIDS Cohort Study Group founded the Chilean
Cohort in 2001. During the study period, this project prospectively
recorded patient data from 29 of the 32 public HIV centers. Patients
were included if they were at least 18 years old and eligible for the
initiation of ART according to the Chilean HIV/AIDS guidelines.
During our study period, ART was recommended for patients with
symptomatic HIV infection (Centers for Disease Control and
Prevention (CDC) stage B/C), or for asymptomatic patients with
CD4+ counts of <200 cells/ml.30 All patients included in this
database were ART-naive at entry and were followed-up twice
yearly using standardized forms, which included demographic and
clinical data as well as laboratory examinations.
Our study analyzed data from October 2001 to October 2007. Of
all patients who were added to the database during this period, only
those who had at least one test result for HBsAg were included in the
study. Assays were performed at local laboratories and therefore
derived from different manufacturers. HIV patients were catego-
rized as hepatitis B co-infected if they had at least one positive result
for HBsAg testing (HBsAg-positive). HIV patients with only negative
results for HBsAg served as a control group (HBsAg-negative).
Mortality data were analyzed and survival times were calculated for
HBsAg-positive and HBsAg-negative patient groups.
Of the included patients, only those who provided a complete
set of CD4+ cell counts and plasma viral load (VL) at baseline (0–6
weeks) and at follow-up after 6–18 months, were included in the
analysis of treatment response. If more than one CD4+ cell count or
VL was recorded at follow-up, the value closest to 12 months was
taken for the analysis. Virological response was deﬁned as a VL
<500 copies/ml, and immunological response as an increase of
CD4+ cells >100 cells/ml from baseline to the time of follow-up.
According to these laboratory values, patients were categorized
into four different groups of treatment outcome: virological and
immunological response (VL+/CD4+), immunological response
only (VL/CD+), virological response only (VL+/CD4), and no
response (VL/CD4). CD4+ cell counts were determined by
standard ﬂow cytometry methodology; for VL the NucliSENS HIV-1
assay (bioMe´rieux, Durham NC, USA) with a detection limit of 80
copies/ml was used.
The statistical analysis was performed using PASW Statistics
(PASW Statistics Version 18.0, IBM, New York, USA). Continuous
variables were presented as means with a standard deviation (SD)
and compared between the groups with the Student’s t-test.
Categorical data were presented as counts and percentages, and
the Chi-square test was used to look at differences between groups.
Mortality rates show the overall mortality over 100 person-years
at risk with 95% conﬁdence intervals (95% CI). Information aboutsurvival was censored at the last available entry that was recorded
for each individual patient, or at the day of a fatal event. Kaplan–
Meier survival curves were used to graph survival time. Cox
regression models were used to investigate the association of
potential risk factors with overall mortality. The covariates, sex,
age at beginning of ART (<40 vs. >40 years), baseline CD4+ cell
count (<100 vs. >100 cells/ml), and baseline VL (<100 000 vs.
>100 000 copies/ml) were entered simultaneously into the model.
The selection of covariates is based on their prior identiﬁcation as
substantial risk factors for mortality in the literature.
The corresponding ethics committee approved the project of
the Chilean AIDS Cohort and waived informed consent require-
ments. All patient data were handled anonymously. Unique non-
identiﬁable codes were used for each patient.
3. Results
Our study cohort consisted of 5115 ART-naive HIV patients, of
whom 1907 (37.3%) provided HBsAg test results and were included
in the study. Of these, 161 patients were HBsAg-positive, resulting
in a prevalence of 8.4% HBV/HIV co-infection. Among all studied
patients, 1435 (75.2%) provided a full set of immunological and
virological data and were included in the treatment response
analysis (Figure 1).
As shown in Table 1, signiﬁcantly more patients in the HBsAg-
positive group were found to be male (96.9% vs. 83.7%, p < 0.01).
The route of transmission was predominantly homosexual in both
groups, with a signiﬁcantly higher percentage in the HBsAg-
positive patients (p < 0.01). There was no intravenous drug use
reported in either group. Serological testing for syphilis (VDRL,
venereal disease research laboratory test) was more frequently
positive in the HBsAg-positive patients (20.5% vs. 14.9%); this
difference did not reach statistical signiﬁcance. Most patients
presented in CDC categories A and C. Groups did not differ by their
baseline CDC classiﬁcation, or show signiﬁcant differences in the
spectrum of opportunistic infections at baseline. Opportunistic
infections with the highest frequencies were oral candidiasis and
Pneumocystis jirovecii infection.
At 2.15 (95% CI 0.7–3.7) per 100 person-years, the mortality rate
of the HBsAg-positive group was higher than that of the HBsAg-
negative group with 1.77 (95% CI 1.3–2.2) per 100 person-years;
this difference, resulting in a mortality rate ratio of 1.22 (95% CI
0.58–2.54), was not statistically signiﬁcant. Further analysis by
Table 1
Characteristics of patients of the Chilean AIDS Cohort, grouped by hepatitis B co-infection (HBsAg-positive and HBsAg-negative)
Characteristica All subjects
(n = 1907)
HBsAg-positive
(n = 161)
HBsAg-negative
(n = 1746)
p-Value
Age at start of ART, mean (SD) 37.2 (9.9) 36.8 (9.5) 37.2 (9.9) 0.62
Male sex, n (%) 1617 (84.8) 156 (96.9) 1461 (83.7) <0.01b
Person-years of follow-up time/patient (mean, SD) 2.12 (1.45) 2.30 (1.58) 2.10 (1.43) 0.08
VDRL once positive, n (%) 293 (15.4) 33 (20.5) 260 (14.9) 0.06
Hepatitis C, n (%) 26 (1.4) 3 (1.9) 23 (1.3) 0.57
Route of transmission, n (%)
Homosexual 990 (61.5) 105 (79.5) 885 (59.8) <0.01b
Heterosexual 563 (35.0) 24 (18.2) 539 (36.4) <0.01b
Intravenous drug users 0 0 0
Other 57 (3.5) 3 (2.3) 56 (3.8) 0.35
No data 297 (15.6) 31 (19.3) 266 (15.2) 0.18
Baseline CDC classiﬁcation, n (%)
Class A 617 (32.9) 49 (30.8) 568 (33.1) 0.59
Class B 504 (26.9) 39 (24.5) 465 (27.1) 0.51
Class C 755 (40.2) 71 (44.7) 684 (39.8) 0.22
No data 31 (1.6) 2 (1.2) 29 (1.7) 0.69
Baseline opportunistic infections, n (%)
Pneumocystis 306 (16.0) 27 (16.8) 279 (16.0) 0.79
Tuberculosis 120 (6.3) 7 (4.3) 113 (6.5) 0.29
CMV infection 10 (5.2) 0 (0) 10 (5.7) 0.34
Oral Candida 467 (24.5) 38 (23.6) 429 (24.6) 0.78
Others 332 (17.4) 34 (21.1) 298 (17.1) 0.19
No opportunistic infection 672 (32.2) 55 (34.2) 617 (35.3) 0.77
ART, antiretroviral therapy; CDC, Centers for Disease Control and Prevention; CMV, cytomegalovirus; HBsAg, hepatitis B surface antigen; SD, standard deviation; VDRL,
venereal disease research laboratory test.
a Continuous variables of the groups (HBsAg-positive, HBsAg-negative) were compared with the Student’s t-test, categorical variables by Chi-square test.
b Signiﬁcant differences.
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survival times of HBsAg-positive and HBsAg-negative patients
(Figure 2). Cox regression analysis including the covariates sex, age
at beginning of ART (<40 vs. >40 years), baseline CD4+ cells count
(<100 vs. >100 cells/ml), and baseline VL (<100 000 vs. >100 000
copies/ml) did not change the estimates signiﬁcantly.
Treatment response data are presented in Table 2. Baseline
immunological data did not show any signiﬁcant differences
between the HBsAg-positive and HBsAg-negative patients, with a
mean baseline CD4+ cell count of 138 (SD 112) cells/ml and 125 (SD
96) cells/ml, respectively. Severe immunosuppression at baselineFigure 2. Kaplan–Meier survival curves for the Chilean AIDS Cohort (n = 1907),
grouped by HBsAg-positive (dotted line) and HBsAg-negative (solid line) patients.with CD4+ cell counts <100 cells/ml was observed in 53.4% of
HBsAg-positive and 58.5% of HBsAg-negative patients. Baseline VL
>100 000 copies/ml was detected in 69.5% of HBsAg-positive
patients and 63.7% of HBsAg-negative patients. Analysis of
immunological and virological treatment response rates after 12
months of ART did not reveal signiﬁcant differences between the
two groups. The mean increase in CD4+ cell count was +154 (SD
128) cell/ml for the HBsAg-positive patient group and +162 (SD
139) cells/ml for the HBsAg-negative patient group. Analysis of
discordant response revealed no signiﬁcant differences in the
distribution of HBsAg-positive and HBsAg-negative patients
within the four treatment response groups.
The use of selected ART drugs in the study population is
summarized in Table 3. Lamivudine was prescribed in 98.7% of HIV
therapies and there was no difference between the HBV co-
infected and not co-infected patients. Only seven patients received
tenofovir during the study period; among these were signiﬁcantly
more hepatitis B co-infected patients (p < 0.01). The use of
nevirapine and efavirenz did not differ between groups. One
(p < 0.01) or more than two treatment changes (p < 0.05) were
recorded signiﬁcantly more frequently in the HBV co-infected
group.
4. Discussion
Most epidemiological studies on HBV/HIV co-infection describe
populations in industrialized countries in Europe and North
America, whereas the situation in Latin America is less well
studied. Our study provides the ﬁrst information on hepatitis B co-
infection within the Chilean AIDS Cohort, which includes public
HIV care centers of the country. Epidemiological information on
the prevalence of HBV/HIV co-infection in Chile is limited. Our data
show a prevalence of 8.4% (95% CI 7.3–9.8%), indicating that the
burden of HBV co-infection might have been underestimated in a
previous study, which described a prevalence of 6.1% (95% CI 3.8–
9.5%).7 Furthermore, our study highlights that HIV patients have a
more than 50-fold increased risk of HBV infection compared to the
general population in Chile. Until now, an HBV vaccine has not
Table 2
Treatment response after 12 months of ART, grouped by hepatitis B co-infection (HBsAg-positive and HBsAg-negative)
All subjects
(n = 1435)
HBsAg-positive
(n = 118)
HBsAg-negative
(n = 1317)
p-Value
Baseline parametersa
CD4+ cells/ml, mean (SD) 125 (97) 138 (112) 125 (96) 0.15
CD4+ <100 cells/ml, n (%) 833 (58.0) 63 (53.4) 770 (58.5) 0.28
Viral load, copies/ml, mean (SD) 343 213 (797 037) 329 079 (475 808) 344 488 (819 976) 0.85
Viral load >100 000 copies/ml, n (%) 921 (64.2) 82 (69.5) 839 (63.7) 0.21
Response after 12 month of ARTa
Increase of CD4 cells/ml, mean (SD) 162 (139) 154 (128) 162 (139) 0.53
Viral load <400 copies/ml, n (%) 1186 (82.6) 95 (80.5) 1091 (82.8) 0.52
CD4+ increase >100 cells/ml, n (%) 960 (66.9) 76 (64.4) 884 (67.1) 0.55
Virological + immunological successb, n (%)
VL+/CD4+
852 (59.4) 69 (58.5) 783 (59.5) 0.84
Immunological success onlyb, n (%)
VL/CD4+
108 (7.5) 7 (5.9) 101 (7.7) 0.49
Virological success onlyb, n (%)
VL+/CD4
334 (23.3) 26 (22.0) 308 (23.4) 0.74
No responseb, n (%)
VL/CD4
141 (9.8) 16 (13.6) 125 (9.5) 0.15
ART, antiretroviral therapy; HBsAg, hepatitis B surface antigen; SD, standard deviation; VL, viral load.
a Continuous variables of the groups (HBsAg-positive, HBsAg-negative) were compared with the Student’s t-test, categorical variables by Chi-square test.
b Virological treatment success was deﬁned as plasma VL <400 copies/ml after 12 month of therapy. Immunological treatment success was deﬁned as an increase in CD4+
cells of 100/ml or more after 12 months of therapy.
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health system. Our data indicate that this policy should be revised
and vaccination strategies should be discussed.
The epidemiology of HBV/HIV co-infection is complex and not
completely understood, but co-infection rates depend on the
prevalence of HBV in the general population,2,14 the dominant
routes of HIV infection,31 and the coverage of HBV immunization.32
In our study population, co-infection was mainly associated with
sexual transmission in homosexual men, conﬁrming the existing
data.33,34 Our study and previous analysis of the Chilean AIDS
Cohort showed that intravenous drug use, a known risk factor for
co-infection,31 is virtually absent in Chile. Surprisingly, this did not
lead to a signiﬁcantly lower rate of co-infection in comparison to
European HIV cohorts with a much higher rate of intravenous drug
use. In Denmark, for example, a prevalence of 6.1% HBV co-
infection was found in the national HIV cohort reporting
intravenous drug use in 9.7% of patients.18 The inﬂuence of a high
background prevalence within the general population on HBV/HIV
co-infection also seems complex. An HIV cohort from Thailand
with 82% heterosexual transmission and 1% intravenous drug use
reported HBV co-infection in 8.7% of patients, although the
prevalence of chronic HBV in blood donors in Thailand is estimated
at 2.6%,35 which is 17-times higher than in Chile.4
In South America, the Amazon basin is an area of high
endemicity of hepatitis B,36 whereas other regions have a lowTable 3
Selected antiretroviral drugs in the study population, grouped by hepatitis B co-infe
negative) were compared with the Chi-square test.
All subjects
(n = 1907)
HBsAg-po
(n = 161)
Drugs, n (%)
Tenofovira 7 (0.4) 4 (2.5)
Lamivudine 1882 (98.7) 157 (97.5
Efavirenz 1451 (76.1) 122 (75.8
Nevirapine 317 (16.6) 18 (11.2
Changes of therapy, n (%)
1 592 (31.0) 65 (40.4
2 197 (10.3) 22 (13.7
>2 62 (3.3) 10 (6.2)
HBsAg, hepatitis B surface antigen.
a Tenofovir was not widely available in Chile during the study period.
b Signiﬁcant differences.rate of hepatitis B infection. Comprehensive data on HBV/HIV co-
infection in South America are lacking. In Brazil, for example,
marked geographical differences with rates ranging from 3% to 24%
have been reported.37Most other reports from South America have
lacked a broad population base and have mostly focused on
subgroups of HIV-infected patients. In Peru, a prevalence of 9.5%
HBsAg was published for HIV-positive men who have sex with
men.38 In a Colombian study, only patients positive for antibodies
to the hepatitis B core antigen (anti-HBc) were tested for HBsAg,
resulting in a prevalence of 2.1%.34 Data from Argentina that were
taken as a part of the EuroSIDA multicenter study, showed a
relatively high prevalence of 17.8% HBsAg positivity,39 in accor-
dance with older data.40 This high prevalence was mainly
attributed to intravenous drug use. A more recent study from
2010 found only 3.3% HBsAg-positives in a series of 593 HIV-
positive patients in Buenos Aires. The authors state that political
changes have led to a decrease in injecting drug use, resulting in a
lower HBV/HIV prevalence since 1999.41 The lack of comprehen-
sive data and the heterogeneity of the existing evidence show a
need for further studies on HBV co-infection in South America.
The inﬂuence of HBV co-infection on the mortality of HIV
patients is a controversial subject. Large studies such as EuroSIDA
found a signiﬁcantly higher mortality for HBV co-infected in
comparison to not co-infected HIV patients (3.7 vs. 2.6 per 100
person-years). This difference was mostly due to liver-relatedction (HBsAg-positive and HBsAg-negative). Groups (HBsAg-positive and HBsAg-
sitive HBsAg-negative
(n = 1746)
p-Value
 3 (0.2) <0.01b
) 1725 (98.8) 0.17
) 1329 (76.1) 0.92
) 299 (17.1) 0.05b
) 527 (30.2) <0.01b
) 175 (10.0) 0.14
 52 (3.0) <0.05b
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cohort from Denmark also found signiﬁcantly higher mortality
rates for HBsAg-positive compared to HBsAg-negative patients, 3.9
and 2.5 per 100 person-years, respectively.18 The Multicenter AIDS
Cohort Study (MACS), which includes male HIV patients in the USA,
did not conﬁrm this ﬁnding,12 although in accordance with other
studies, liver-related deaths were more frequent in co-infected
patients.14 In our study, we were not able to ﬁnd an inﬂuence of
HBsAg carrier status on survival. HBsAg-positive patients had a
mortality rate of 2.15 (95% CI 0.7–3.7) per 100 person-years
compared to 1.77 (95% CI 1.3–2.2) in the HBsAg-negative group,
resulting in a mortality rate ratio of 1.22 (95% CI 0.58–2.54). A
possible reason for these differences is that our cohort, as with the
MACS study group, did not include intravenous drug users.
Additionally, the distribution of hepatitis B genotypes might
inﬂuence survival rates in different cohorts. Still, this cannot
explain the above-mentioned differences, since in Chile genotype F
is predominant and this genotype is associated with a higher
mortality compared to genotypes A and D, which occur more
frequently in Europe and North America.5,6
Low CD4 cell counts are considered a risk factor for liver-related
mortality for HBV/HIV co-infected patients as well as for overall
mortality in HIV patients regardless of their HBV status.12,42 The
EuroSIDA study found a lower mean baseline CD4+ cell count in the
HBV co-infected HIV patients compared to the HBV-negative HIV
patients (232 cells/ml vs. 275 cells/ml).39 In contrast, the baseline
mean CD4+ cell counts of our cohort were slightly higher in
hepatitis B co-infected patients (138 cells/ml vs. 125 cells/ml),
which is in accordance with other studies.12,43 We integrated
baseline CD4+ cell counts into our regression model and results
remained unchanged. No inﬂuence of CD4+ cell counts on
mortality was found in our data.
Another important factor in HBV co-infection is the increased
risk of severe hepatotoxic side effects caused by antiretroviral
drugs.44,45 In our database, liver enzymes were not documented on
a regular basis, thus hepatotoxicity could not be analyzed.
However, we noticed signiﬁcantly more ART changes in the HBV
co-infected group, and hepatotoxic drug effects could have been
one important reason for changing ART.
HBV/HIV co-infection is an important factor for the selection of
an antiretroviral regimen. The Chilean public health system
provides ART drugs free of charge, but the choice of drugs is
predetermined by national guidelines. At the time of data
collection, the standard treatment regimen consisted of a
backbone of lamivudine and zidovudine combined with efavirenz
or nevirapine. Therefore almost all our patients (98.7%) received
lamivudine, without signiﬁcant differences between study groups.
Monotherapy with lamivudine in HBV-infected patients can lead
to resistance in about 20% of cases per year. Nevertheless, an inter-
cohort analysis of HBsAg-positive HIV patients found a reduced
liver-related mortality associated with lamivudine use in combi-
nation therapies.46 The high coverage of lamivudine in our study
could have led to a decrease in mortality in the HBV co-infected
patients, diminishing the difference between the two groups.
Although tenofovir was used signiﬁcantly more often in the HBV
co-infected group, its overall use was negligible (seven of 1907
patients), since it was not widely available in the public health
system of Chile until 2010.
After a period of 12 months of ART, we did not ﬁnd a signiﬁcant
impact of HBV co-infection on immunological or virological
treatment response in our cohort of treatment-naive patients. This
is in accordance with data of the international HIV-NAT cohort after
48 weeks of treatment.17 In contrast to our ﬁndings, a Taiwanese
study described a signiﬁcantly higher rate of virological failure in the
HBV/HIV co-infected group.19 The authors argue that a higher
incidence of hepatitis and frequent treatment interruptions mightexplain this inﬂuence on virological response. Still, this study was
performed in a population with a high HBV prevalence, resulting in a
much higher HBV/HIV co-infection rate of 21.7% than in our study.
Various other studies have reported ﬁndings in accordance with
those of our study and did not show a negative inﬂuence of HBV co-
infection on the virological treatment outcome.16,17,20
Our study also aimed to analyze the potential inﬂuence of HBV
co-infection on the incidence of discordant treatment response to
ART. Such an association has been suggested for cytomegalovirus
(CMV),47 supporting the hypothesis that viral co-infections might
interfere with CD4+ cell recovery. However, hepatitis C co-
infection did not show an association with discordant response
in the multivariate logistic regression model of Moore and co-
workers.26 To our knowledge, HBV has never been investigated as a
risk factor in this context. Our data could not support the
hypothesis that an association between HBV co-infection and
discordant treatment response is relevant.
A limitation of our study was that HBsAg testing was not
available for all patients in the Chilean AIDS Cohort, since this test
was not performed as part of the routine at all HIV centers,
selection bias cannot be excluded. Nevertheless, baseline char-
acteristics of the 1907 patients included did not differ from those of
the entire cohort of 5115 patients described in an earlier
publication.48 One important factor is the rate of homosexual
transmission, which was 61.5% (95% CI 59.1–63.8) in our study
population and 58% (95% CI 56.7–59.4) in the whole cohort. High
dropout rates have also been a problem in other cohort studies
such as EuroSIDA and MACS, where 43% and 32% of HIV patients,
respectively, had to be excluded, because of missing HBsAg test
results. Intensiﬁed HBsAg testing, which is recommended by new
Chilean guidelines,49 will help to include more patients in future
studies. Another limitation of our study is the lack of a complete set
of serological markers of HBV and other important parameters
such as HBV viral load, HBV genotype, liver enzymes, and hepatitis
D co-infection. Due to limited ﬁnancial resources in many
countries including Chile, HBsAg is the only test widely available,
therefore the case deﬁnition used in our study is common in
prevalence studies of chronic HBV infection in resource-poor
settings. Still, it creates a heterogeneous group, which includes
cases of chronic active and inactive HBV. Studies analyzing
different subgroups deﬁned by serological markers within the
population of HIV patients in Chile are currently underway.
In conclusion, our study revealed a prevalence of chronic HBV
infection of 8.4% within the Chilean HIV population, which
indicates a markedly elevated HBV risk compared to the general
population. Treatment response and overall mortality after 12
months of ART were not inﬂuenced by HBV co-infection. Still, in
patients with hepatitis B co-infection, the ART regimen was more
frequently changed than in those without co-infection, which
might be related to a higher risk of hepatotoxic drug effects. Our
analysis reﬂects the problems in an upper middle-income South
American country, where up to now epidemiological and clinical
features of HBV/HIV co-infection have been poorly studied, and
neither HBV serological testing nor vaccination is widely available
for HIV patients. Further studies will help to overcome these
obstacles and assist in the planning of targeted immunization
programs in this setting.
Acknowledgements
We would like to thank the staff of the Fundacio´n Arriara´n and
the Chilean AIDS Cohort study group, especially Gladys Allendes,
Ange´lica Carrasco, Erika Jimenez, Karina Urriola, Rocı´o Ferna´ndez,
Omar Morales, and Manuel Mun˜oz for their support and help with
the collection of data.
R. Otto-Knapp et al. / International Journal of Infectious Diseases 17 (2013) e919–e924e924Conﬂict of interest: The authors declare no conﬂicts of interest.
References
1. Kourtis AP, Bulterys M, Hu DJ, Jamieson DJ. HIV–HBV coinfection—a global
challenge. N Engl J Med 2012;366:1749–52.
2. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol
2006;44(1 Suppl):S6–9.
3. Boesecke C, Wasmuth JC, Hepatitis B. In: Mauss S, Berg T, Rockstroh J, Sarrazin C,
Wedemeyer H, editors. Hepatology: a clinical textbook. Third ed., H. Flying
Publisher; 2012. p. 32–43.
4. Ministry of Health. Encuesta Nacional de Salud 2009-2010. Chile: Ministerio de
Salud; 2011, Available at: http://www.minsal.cl/portal/url/item/bcb03d7bc28b64
dfe040010165012d23.pdf (accessed February 2013).
5. Venegas M, Munos G, Hurtado C, Alvarez L, Velasco M, Villanueva RA, et al.
Prevalence of hepatitis B virus genotypes in chronic carriers in Santiago. Chile
Arch Virol 2008;153:2129–32.
6. Sanchez-Tapias JM, Costa J, Mas A, Bruguera M, Rodes J. Inﬂuence of hepatitis B
virus genotype on the long-term outcome of chronic hepatitis B in Western
patients. Gastroenterology 2002;123:1848–56.
7. Pe´rez CC, Cero´n AI, Fuentes LG, Zan˜artu SC, Balcells MM, Ajenjo HC, et al.
Hepatitis B, C Treponema pallidum and Toxoplasma gondii co-infections in HIV
infected patients. Rev Med Chil 2009;137:641–8.
8. Eskild A, Magnus P, Petersen G, Sohlberg C, Jensen F, Kittelsen P, et al. Hepatitis B
antibodies in HIV-infected homosexual men are associated with more rapid
progression to AIDS. AIDS 1992;6:571–4.
9. Ockenga J, Tillmann HL, Trautwein C, Stoll M, Manns MP, Schmidt RE. Hepatitis
B and C in HIV-infected patients. Prevalence and prognostic value. J Hepatol
1997;27:18–24.
10. Scharschmidt BF, Held MJ, Hollander HH, Read AE, Lavine JE, Veereman G, et al.
Hepatitis B. in patients with HIV infection: relationship to AIDS and patient
survival. Ann Intern Med 1992;117:837–8.
11. Sinicco A, Raiteri R, Sciandra M, Bertone C, Lingua A, Salassa B, et al. Coinfection
and superinfection of hepatitis B virus in patients infected with human immu-
nodeﬁciency virus: no evidence of faster progression to AIDS. Scand J Infect Dis
1997;29:111–5.
12. Thio CL, Seaberg EC, Skolasky Jr R, Phair J, Visscher B, Mun˜oz A, et al. HIV-1,
hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort
Study (MACS). Lancet 2002;360:1921–6.
13. Idoko J, Meloni S, Muazu M, Nimzing L, Badung B, Hawkins C, et al. Impact of
hepatitis B virus infection on human immunodeﬁciency virus response to
antiretroviral therapy in Nigeria. Clin Infect Dis 2009;49:1268–73.
14. Thio CL. Hepatitis B and human immunodeﬁciency virus coinfection. Hepatol-
ogy 2009;49(5 Suppl):S138–45.
15. Hoffmann CJ, Charalambous S, Martin DJ, Innes C, Churchyard GJ, Chaisson RE,
et al. Hepatitis B virus infection and response to antiretroviral therapy (ART) in
a South African ART program. Clin Infect Dis 2008;47:1479–85.
16. Hoffmann CJ, Seaberg EC, Young S, Witt MD, D’Acunto K, Phair J, et al. Hepatitis
B and long-term HIV outcomes in coinfected HAART recipients. AIDS
2009;23:1881–9.
17. Law WP, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, Lange JM,
et al. Impact of viral hepatitis co-infection on response to antiretroviral therapy
and HIV disease progression in the HIV-NAT cohort. AIDS 2004;18:1169–77.
18. Omland LH, Weis N, Skinhøj P, Laursen A, Christensen PB, Nielsen HI, et al.
Impact of hepatitis B virus co-infection on response to highly active antiretro-
viral treatment and outcome in HIV-infected individuals: a nationwide cohort
study. HIV Med 2008;9:300–6.
19. Sheng WH, Chen MY, Hsieh SM, Hsiao CF, Wang JT, Hung CC, et al. Impact of
chronic hepatitis B virus (HBV) infection on outcomes of patients infected with
HIV in an area where HBV infection is hyperendemic. Clin Infect Dis
2004;38:1471–7.
20. Taylor BC, Yuan JM, Shamliyan TA, Shaukat A, Kane RL, Wilt TJ. Clinical out-
comes in adults with chronic hepatitis B in association with patient and viral
characteristics: a systematic review of evidence. Hepatology 2009;49(5
Suppl):S85–95.
21. Piketty C, Weiss L, Thomas F, Mohamed AS, Belec L, Kazatchkine MD. Long-term
clinical outcome of human immunodeﬁciency virus-infected patients with
discordant immunologic and virologic responses to a protease inhibitor-con-
taining regimen. J Infect Dis 2001;183:1328–35.
22. Tan R, Westfall AO, Willig JH, Mugavero MJ, Saag MS, Kaslow RA, et al. Clinical
outcome of HIV-infected antiretroviral-naive patients with discordant immu-
nologic and virologic responses to highly active antiretroviral therapy. J Acquir
Immune Deﬁc Syndr 2008;47:553–8.
23. Zoufaly A, an der Heiden M, Kollan C, Bogner JR, Fa¨tkenheuer G, Wasmuth JC, et al.
Clinical outcome of HIV-infected patients with discordant virological and immu-
nological response to antiretroviral therapy. J Infect Dis 2011;203:364–71.
24. Tuboi SH, Brinkhof MW, Egger M, Stone RA, Braitstein P, Nash D, et al. Discor-
dant responses to potent antiretroviral treatment in previously naive HIV-1-
infected adults initiating treatment in resource-constrained countries: the
antiretroviral therapy in low-income countries (ART-LINC) collaboration. J
Acquir Immune Deﬁc Syndr 2007;45:52–9.25. Florence E, Lundgren J, Dreezen C, Fisher M, Kirk O, Blaxhult A, et al. Factors
associated with a reduced CD4 lymphocyte count response to HAART despite
full viral suppression in the EuroSIDA study. HIV Med 2003;4:255–62.
26. Moore DM, Hogg RS, Yip B, Wood E, Tyndall M, Braitstein P, et al. Discordant
immunologic and virologic responses to highly active antiretroviral therapy are
associated with increased mortality and poor adherence to therapy. J Acquir
Immune Deﬁc Syndr 2005;40:288–93.
27. Julg B, Poole D, Ghebremichael M, Castilla C, Altfeld M, Sunpath H, et al. Factors
predicting discordant virological and immunological responses to antiretrovi-
ral therapy in HIV-1 clade C infected Zulu/Xhosa in South Africa. PLoS One
2012;7:e31161.
28. Molina-Pinelo S, Leal M, Soriano-Sarabia N, Gutie´rrez S, Fernandez G, Mun˜oz-
Ferna´ndez MA, et al. Prevalence and factors involved in discordant responses to
highly active antiretroviral treatment in a closely followed cohort of treatment-
naı¨ve HIV-infected patients. J Clin Virol 2005;33:110–5.
29. Wolff MJ, Beltra´n CJ, Va´squez P, Ayala MX, Valenzuela M, Berrı´os G, et al. The
Chilean AIDS Cohort: a model for evaluating the impact of an expanded access
program to antiretroviral therapy in a middle-income country—organization
and preliminary results. J Acquir Immune Deﬁc Syndr 2005;40:551–7.
30. Gobierno de Chile Ministerio de Salud. Acquired immunodeﬁciency syndrome.
Rev Chilena Infectol 2010;27:239–76.
31. Puoti M, Airoldi M, Bruno R, Zanini B, Spinetti A, Pezzoli C, et al. Hepatitis B virus
co-infection in human immunodeﬁciency virus-infected subjects. AIDS Rev
2002;4:27–35.
32. Wang C, Wang Y, Huang X, Li X, Zhang T, Song M, et al. Prevalence and factors
associated with hepatitis B immunization and infection among men who have
sex with men in Beijing. China PLoS One 2012;7:e48219.
33. Hadler SC, Judson FN, O’Malley PM, Altman NL, Penley K, Buchbinder S, et al.
Outcome of hepatitis B virus infection in homosexual men and its relation to
prior human immunodeﬁciency virus infection. J Infect Dis 1991;163:454–9.
34. Hoyos-Orrego A, Massaro-Ceballos M, Ospina-Ospina M, Go´mez-Builes C,
Vanegas-Arroyave N, Tobo´n-Pereira J, et al. Serological markers and risk factors
for hepatitis B and C viruses in patients infected with human immunodeﬁciency
virus. Rev Inst Med Trop Sao Paulo 2006;48:321–6.
35. Chimparlee N, Oota S, Phikulsod S, Tangkijvanich P, Poovorawan Y. Hepatitis B
and hepatitis C virus in Thai blood donors. Southeast Asian J Trop Med Public
Health 2011;42:609–15.
36. Centers for Disease Control and Prevention. Epidemiology of vaccine-preventable
diseases. Chapter 9: Hepatitis B. Atlanta, GA: CDC; 2012, Available at: http://
www.cdc.gov/vaccines/pubs/pinkbook/hepb.html (accessed February 2013).
37. de Almeida Pereira RA, Mussi AD, de Azevedo e Silva VC, Souto FJ. Hepatitis B
virus infection in HIV-positive population in Brazil: results of a survey in the
state of Mato Grosso and a comparative analysis with other regions of Brazil.
BMC Infect Dis 2006;6:34.
38. Lama JR, Agurto HS, Guanira JV, Ganoza C, Casapia M, Ojeda N, et al. Hepatitis B
infection and association with other sexually transmitted infections among
men who have sex with men in Peru. Am J Trop Med Hyg 2010;83:194–200.
39. Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, et al.
Hepatitis B and HIV: prevalence, AIDS progression, response to highly active
antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS
2005;19:593–601.
40. Fainboim H, Gonza´lez J, Fassio E, Martı´nez A, Otegui L, Eposto M, et al. Preva-
lence of hepatitis viruses in an anti-human immunodeﬁciency virus-positive
population from Argentina. A multicentre study. J Viral Hepat 1999;6:53–7.
41. Laufer N, Quarleri J, Bouzas MB, Juncos G, Cabrini M, Moretti F, et al. Hepatitis B
virus, hepatitis C virus and HIV coinfection among people living with HIV/AIDS
in Buenos Aires, Argentina. Sex Transm Dis 2010;37:342–3.
42. Bonacini M, Louie S, Bzowej N, Wohl AR. Survival in patients with HIV infection
and viral hepatitis B or C: a cohort study. AIDS 2004;18:2039–45.
43. Lincoln D, Petoumenos K, Dore GJ, Australian HIV. Observational Database. HIV/
HBV and HIV/HCV coinfection, and outcomes following highly active antiretro-
viral therapy. HIV Med 2003;4:241–9.
44. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity
associated with nevirapine or efavirenz-containing antiretroviral therapy: role
of hepatitis C and B infections. Hepatology 2002;35:182–9.
45. Martı´nez E, Blanco JL, Arnaiz JA, Pe´rez-Cuevas JB, Mocroft A, Cruceta A, et al.
Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing an-
tiretroviral therapy. AIDS 2001;15:1261–8.
46. Puoti M, Cozzi-Lepri A, Paraninfo G, Arici C, Moller NF, Lundgren JD, et al. Impact
of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-
positive individuals: results from an inter-cohort analysis. Antivir Ther (Lond)
2006;11:567–74.
47. Goossens VJ, Schreij G, van der Geest S, Van Leeuwen DM, Baas DC, Bruggeman
CA, et al. A delay in CD4 cell response after initiation of highly active antiretro-
viral therapy is associated with the presence of anti-cytomegalovirus but not
with anti-herpes simplex virus antibodies. AIDS 2002;16:1682–4.
48. Wolff MJ, Corte´s CP, Shepherd BE, Beltra´n CJ. Chilean AIDS Cohort Study Group.
Long-term outcomes of a national expanded access program to antiretroviral
therapy: the Chilean AIDS Cohort. J Acquir Immune Deﬁc Syndr 2010;55:368–74.
49. Gobierno de Chile, Ministerio de Salud, Chile. Acquired immunodeﬁciency
syndrome. Rev Chil Infectol 2010;27:239–76.
